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32% in ALF patients. All patients with fungal infection had
concomitant bacterial infections. Deterioration in HE after
initial improvement, unresponsive pyrexia, renal failure,
and a high leukocyte count despite antibiotics, were clinical
clues to an underlying fungal infection.
The most common site of infection in our patients was the
respiratory tract. Since two-thirds of all deaths occur within
ﬁrst 72 hours and the median time to positive cultures was
4.5 days in our patients, we advocate prophylactic systemic
antibiotics in all ALF patients at admission according to
local sensitivity patterns. Enteral decontamination regimes
need not be added to systemic antibiotics. Improvement
in neutrophil phagocytosis and killing has been shown
both in-vitro and in-vivo by G-CSF. Recently ammonia has
been shown to directly inhibit neutrophil function in vivo,
and ammonia lowering treatments in ALF are a promising
strategy for the future.
I-52 TIPS (transjugular intrahepatic portosystemic
shunts) in the treatment of complications of portal
hypertension
D.M. Brooks *. Austin Hospital, Heidelberg, Australia
Chronic liver disease and its complications are common
throughout the world. Signiﬁcant regional variation exists,
but hepatitis B and C and alcohol abuse account for
around 90% of cases. Autoimmune chronic active hepatitis,
primary and secondary biliary cirrhosis, hemochromatosis,
Budd Chiari syndrome and other rare conditions make up
the remaining 10%. Risk of death comes from variceal
bleeding, progressive liver failure and hepatoma. Among
the important quality of life issues are management of
ascites and hepatic encephalopathy.
Ideally these patients are treated with liver transplantation
however for many patients this treatment is unsuitable or
unavailable. TIPS can be used to control the complications of
portal hypertension in this group. For best patient outcome
TIPS needs to be combined with best medical management
as part of a multidisciplinary approach. Patient selection
and timing of TIPS are critical to a good clinical outcome.
While TIPS has been available since 1985 its clinical
effectiveness was initially limited by a high rate of shunt
stenosis and occlusion. The introduction of covered TIPS
endoprostheses has signiﬁcantly improved the long term
patency and clinical effectiveness of this procedure.
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Chronic hepatitis C virus (HCV) infection is a major
health problem worldwide because of its potential adverse
sequelae including cirrhosis-related complications and
hepatocellular carcinoma (HCC). Taiwan is a country
endemic for HCV infection, and 30% of Taiwanese patients
with chronic liver diseases are attributable to this virus.
The primary goal of treatment for chronic hepatitis C is to
eliminate HCV replication and therefore reduce or prevent
hepatic injury. Furthermore, the ultimate long-term goal of
therapy is to prevent hepatic decompensation, to reduce or
prevent disease progression to cirrhosis and/or HCC, and to
prolong survival of patients.
In Taiwan, interferon (IFN)-based therapy has long been
used to treat chronic hepatitis C. Our earlier pilot study
showed that naive patients with 3 MU of conventional IFN
thrice weekly plus 1,200mg of oral ribavirin daily for 24
weeks had a signiﬁcantly higher sustained virologic response
(SVR) rate than those with no treatment (43% vs. 6%). A
randomized trial also suggested that more than one-third
Taiwanese chronic hepatitis C patients who failed prior
IFN monotherapy could achieve SVR after 24 weeks of re-
treatment with combination therapy, and the response rate
was even higher (53%) in those with IFN 6 MU. A study
from southern Taiwan also conﬁrmed that 6 MU regimen
has better efﬁcacy than 3 MU regimen in terms of virologic
and histological responses. In addition, sustained virologic
response to interferon-based therapy can result in reducing
HCC incidence and improving patient survival. Similar to
Caucasian patients with chronic hepatitis C, a recent
multicenter randomized study in Taiwan has conﬁrmed that
combination of PEG-IFN and ribavirin therapy for 24 weeks
had signiﬁcantly better SVR and lower relapse rate when
compared to IFN and ribavirin therapy in our genotype 1
chronic hepatitis C patient, whereas both regimens can be
recommended for genotype non-1 patients. Although the
recommended treatment for genotype patients is peg-IFN
plus ribavirin for 48 weeks, whether treatment duration of
24 weeks is as effective as standard treatment in genotype 1
patients with a rapid virological response (RVR; seronegative
for HCV RNA at 4 weeks) remains unclear. Two large-scale
randomized trials in Taiwan all showed that genotype 1
patients derive a signiﬁcantly better SVR from 48 weeks
versus 24 weeks of peginterferon/ribavirin even if they
attain an RVR. Both 24 and 48 weeks of therapy can achieve
high SVR rates in genotype 1 patients with low viral loads
and an RVR. In addition, a randomized study showed that
16 weeks and 24 weeks of peg-IFN treatment with weight-
based ribavirin at a dose of 1000 1200mg/day provided
equal efﬁcacy in genotype 2 patients who achieved rapid
virologic response (RVR) at 4 weeks.
Several speciﬁcally targeted antiviral therapies for
hepatitis C (STAT-C) have been designed to directly inhibit
the replication of HCV, and early preclinical data showed
encouraging results. Therefore, combination therapy with a
backbone of peg-IFN plus ribavirin, or perhaps using several
of these small molecules with distinct modes of action and
resistance proﬁles, will be proven useful in the future.
I-54 Optimizing HCV antiviral treatment: reducing
treatment duration
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The current ‘gold standard’ treatment for patients with
chronic hepatitis C consists of pegylated interferon-alfa
(PEG-IFN) + ribavirin, for a duration of 48 weeks for those
with HCV genotype 1 and 4, and 24 weeks for genotypes
2 and 3. However, these rigid treatment durations are
now being questioned in light of new information on viral
kinetic responses during the early phase of treatment.
In particular, those with a rapid viral response (RVR),
deﬁned as undetectability of HCV-RNA at 4wk after onset of
treatment, may only need a shorter duration of treatment
whether they have genotype 1, 2, or 3. Evidence suggesting
a shorter 24-wk course in genotype 1 RVR patients and
12 16 weeks in those with genoytpes 2/3 will be presented.
Although there are several pre-treatment baseline factors
that may predict sustained virological response (SVR), such
as genotype, viral load, presence of advanced ﬁbrosis, body
weight and ethnicity, one of the strongest predictors of SVR
is the presence of RVR. Regardless of genotype (studied
only for genotypes 1, 2, 3), the presence of RVR appears
